Limits...
Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.

Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu J - BMC Cancer (2009)

Bottom Line: No CRC "specific" classifier was found.In this study, the SELDI-TOF-MS-based protein expression profiling approach did not perform to identify CRC.However, this technique is promising in distinguishing patients with cancer from a non-cancerous population; it may be useful for monitoring recurrence of CRC after treatment.

View Article: PubMed Central - HTML - PubMed

Affiliation: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Colorectal Surgery, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, PR China. wangki2004@126.com

ABSTRACT

Background: Surface enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) analysis on serum samples was reported to be able to detect colorectal cancer (CRC) from normal or control patients. We carried out a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify CRC.

Methods: A retrospective cohort of 338 serum samples including 154 CRCs, 67 control cancers and 117 non-cancerous conditions was profiled using SELDI-TOF-MS.

Results: No CRC "specific" classifier was found. However, a classifier consisting of two protein peaks separates cancer from non-cancerous conditions with high accuracy.

Conclusion: In this study, the SELDI-TOF-MS-based protein expression profiling approach did not perform to identify CRC. However, this technique is promising in distinguishing patients with cancer from a non-cancerous population; it may be useful for monitoring recurrence of CRC after treatment.

Show MeSH

Related in: MedlinePlus

Raw peak spectra generated by two generations IMAC arrays. QC-30 and QC-3, a same QC sample on IMAC 30 and IMAC 3 in year 2008, respectively; N-04 and C-04, a normal and a cancer sample on IMAC 3 in year 2004.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2743709&req=5

Figure 1: Raw peak spectra generated by two generations IMAC arrays. QC-30 and QC-3, a same QC sample on IMAC 30 and IMAC 3 in year 2008, respectively; N-04 and C-04, a normal and a cancer sample on IMAC 3 in year 2004.

Mentions: We previously reported a classifier (composed of two peaks: m/z 8,132 and m/z 4,002) to discriminate CRC patients from healthy volunteers [19]. However, this classifier failed to discriminate CRC patients from healthy volunteers in cohorts of the current study. We then seek to explore reasons for this discrepancy. We used QC samples to generate peaks from an IMAC30 array and a previously preserved IMAC3 array respectively, with the same experimental procedure mentioned above. The m/z drift between the two arrays was less than 0.03%; but the intensities of peaks generated from the two arrays were of great difference (Figure 1), which might be part of the reasons for the inconsistency. Moreover, we also found that the m/z drift in the IMAC3 array through time was less than 0.1%, which manifested the reproducibility of this technique.


Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.

Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu J - BMC Cancer (2009)

Raw peak spectra generated by two generations IMAC arrays. QC-30 and QC-3, a same QC sample on IMAC 30 and IMAC 3 in year 2008, respectively; N-04 and C-04, a normal and a cancer sample on IMAC 3 in year 2004.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2743709&req=5

Figure 1: Raw peak spectra generated by two generations IMAC arrays. QC-30 and QC-3, a same QC sample on IMAC 30 and IMAC 3 in year 2008, respectively; N-04 and C-04, a normal and a cancer sample on IMAC 3 in year 2004.
Mentions: We previously reported a classifier (composed of two peaks: m/z 8,132 and m/z 4,002) to discriminate CRC patients from healthy volunteers [19]. However, this classifier failed to discriminate CRC patients from healthy volunteers in cohorts of the current study. We then seek to explore reasons for this discrepancy. We used QC samples to generate peaks from an IMAC30 array and a previously preserved IMAC3 array respectively, with the same experimental procedure mentioned above. The m/z drift between the two arrays was less than 0.03%; but the intensities of peaks generated from the two arrays were of great difference (Figure 1), which might be part of the reasons for the inconsistency. Moreover, we also found that the m/z drift in the IMAC3 array through time was less than 0.1%, which manifested the reproducibility of this technique.

Bottom Line: No CRC "specific" classifier was found.In this study, the SELDI-TOF-MS-based protein expression profiling approach did not perform to identify CRC.However, this technique is promising in distinguishing patients with cancer from a non-cancerous population; it may be useful for monitoring recurrence of CRC after treatment.

View Article: PubMed Central - HTML - PubMed

Affiliation: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Colorectal Surgery, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, PR China. wangki2004@126.com

ABSTRACT

Background: Surface enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) analysis on serum samples was reported to be able to detect colorectal cancer (CRC) from normal or control patients. We carried out a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify CRC.

Methods: A retrospective cohort of 338 serum samples including 154 CRCs, 67 control cancers and 117 non-cancerous conditions was profiled using SELDI-TOF-MS.

Results: No CRC "specific" classifier was found. However, a classifier consisting of two protein peaks separates cancer from non-cancerous conditions with high accuracy.

Conclusion: In this study, the SELDI-TOF-MS-based protein expression profiling approach did not perform to identify CRC. However, this technique is promising in distinguishing patients with cancer from a non-cancerous population; it may be useful for monitoring recurrence of CRC after treatment.

Show MeSH
Related in: MedlinePlus